RU2001119156A - The expression system for factor VIII - Google Patents

The expression system for factor VIII

Info

Publication number
RU2001119156A
RU2001119156A RU2001119156/13A RU2001119156A RU2001119156A RU 2001119156 A RU2001119156 A RU 2001119156A RU 2001119156/13 A RU2001119156/13 A RU 2001119156/13A RU 2001119156 A RU2001119156 A RU 2001119156A RU 2001119156 A RU2001119156 A RU 2001119156A
Authority
RU
Russia
Prior art keywords
cells
stage
factor viii
protein
human
Prior art date
Application number
RU2001119156/13A
Other languages
Russian (ru)
Other versions
RU2249041C2 (en
Inventor
Миунг-Сэм ЧО
Шэм Йуен ЧЭН
Вильям КЕЛСИ
Хелена ЙИ
Original Assignee
Байер Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/209,916 external-priority patent/US6358703B1/en
Application filed by Байер Корпорейшн filed Critical Байер Корпорейшн
Publication of RU2001119156A publication Critical patent/RU2001119156A/en
Application granted granted Critical
Publication of RU2249041C2 publication Critical patent/RU2249041C2/en

Links

Claims (19)

1. Способ получения клеток, экспрессирующих белок, обладающий прокоагулирующей активностью фактора VIII, включающий следующие последовательные этапы: a) получение клеток исключительно человеческого происхождения, b) взаимодействие клеток стадии а) с вектором в условиях, позволяющих вектору проникнуть в клетки, причем вектор включает селективный маркер и последовательность, кодирующую белок, обладающий прокоагулирующей активностью фактора VIII, оперативно связанную с промотором, c) отбор клеток стадии b) при помощи агента селекции и d) выделение из клеток, полученных на стадии с) отдельных клонов, экспрессирующих большие количества белка, обладающего прокоагулирующей активностью фактора VIII.1. A method of producing cells expressing a protein having procoagulating activity of factor VIII, comprising the following sequential steps: a) obtaining cells of exclusively human origin, b) interaction of the cells of stage a) with the vector under conditions allowing the vector to penetrate the cells, the vector comprising selective marker and sequence encoding a protein having procoagulating activity of factor VIII operably linked to a promoter, c) selection of cells of stage b) using a selection agent and d) isolated and from the cells obtained in step c) of individual clones expressing large amounts of a protein having procoagulating factor VIII activity. 2. Способ по п.1, включающий далее стадию e) адаптации клонов стадии d) к росту в среде, свободной от белков плазмы.2. The method according to claim 1, further comprising stage e) adaptation of the clones of stage d) to growth in a medium free of plasma proteins. 3. Способ по п.1, где клетки стадии а) являются гибридами клеток лимфомы человека и клеток 293 S.3. The method according to claim 1, where the cells of stage a) are hybrids of human lymphoma cells and 293 S. cells. 4. Способ по п.1, где клетки стадии а) являются гибридами клеток 2В8 (АТСС CRL-12569) и клеток 293S.4. The method according to claim 1, where the cells of stage a) are hybrids of 2B8 cells (ATCC CRL-12569) and 293S cells. 5. Способ по п.1, где клетки стадии а) являются клетками НКВ11 (АТСС CRL-12568).5. The method according to claim 1, where the cells of stage a) are NKB11 cells (ATCC CRL-12568). 6. Способ по п.1, где стадии с) и d) выполняются больше, чем один раз.6. The method according to claim 1, where stages c) and d) are performed more than once. 7. Способ по п.1, где последовательность стадии b) кодирует последовательность, представленную на Фиг.1 (SEQ ID NO: 1).7. The method according to claim 1, where the sequence of step b) encodes the sequence shown in Figure 1 (SEQ ID NO: 1). 8. Способ по п.1, где последовательность стадии b) кодирует фактор VIII человека.8. The method according to claim 1, where the sequence of stage b) encodes a human factor VIII. 9. Способ по п.1, где селективный маркер стадии b) - dhfr и агент селекции стадии с) - метотрексат.9. The method according to claim 1, where the selective marker of stage b) is dhfr and the selection agent of stage c) is methotrexate. 10. Способ по п.1, где селективный маркер стадии b) - gs и агент селекции стадии с) - метионин сульфоксиимин.10. The method according to claim 1, where the selective marker of stage b) is gs and the selection agent of stage c) is methionine sulfoxyimine. 11. Способ по п.1, где селективный маркер стадии b) - mdr и агент селекции стадии с) - колхицин.11. The method according to claim 1, where the selective marker of stage b) is mdr and the selection agent of stage c) is colchicine. 12. Способ получения белка, обладающего активностью фактора VIII, включающий выращивание клеток, полученных способом по п.1, в ростовой среде, и дальнейшее выделение из среды белка, обладающего активностью фактора VIII.12. A method of obtaining a protein having a factor VIII activity, comprising growing cells obtained by the method according to claim 1, in a growth medium, and further isolating a protein having a factor VIII activity from the medium. 13. Способ по п.11, где белок является фактором VIII человека.13. The method according to claim 11, where the protein is a human factor VIII. 14. Способ по п.11, где белок имеет аминокислотную последовательность, приведенную на Фиг.1 (SEQ ID NO: 1).14. The method according to claim 11, where the protein has the amino acid sequence shown in Figure 1 (SEQ ID NO: 1). 15. Линия клеток человека, полученная из клеток лимфомы человека и клеток 293S, экспрессирующая на высоком уровне белок, обладающий активностью фактора VIII.15. A human cell line derived from human lymphoma cells and 293S cells expressing at a high level a protein having factor VIII activity. 16. Линия клеток человека по п.14, где линия клеток человека получена из клеток HKB11(ATCCCRL-12568).16. The human cell line of claim 14, wherein the human cell line is derived from HKB11 cells (ATCCCRL-12568). 17. Линия клеток человека, полученная из клеток лимфомы человека и клеток 293S, экспрессирующая на высоком уровне белок, обладающий активностью фактора VIII, при выращивании в среде, свободной от белков плазмы.17. The human cell line obtained from human lymphoma cells and 293S cells, expressing at a high level a protein having the activity of factor VIII, when grown in a medium free of plasma proteins. 18. Клеточная линия по п.16, где клеточная линия получена из клеток НКВ11 (АТСС CRL-12568).18. The cell line according to clause 16, where the cell line is obtained from NKB11 cells (ATCC CRL-12568). 19. Клеточная линия, обозначенная 20В8 (АТСС CRL-12582).19. The cell line designated 20B8 (ATCC CRL-12582).
RU2001119156/13A 1998-12-10 1999-12-08 Method for preparing and isolating protein eliciting activity of factor viii, strain of cells hkb expressing protein eliciting activity of factor viii (variants) RU2249041C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/209,916 US6358703B1 (en) 1998-12-10 1998-12-10 Expression system for factor VIII
US09/209,916 1998-12-10

Publications (2)

Publication Number Publication Date
RU2001119156A true RU2001119156A (en) 2003-07-27
RU2249041C2 RU2249041C2 (en) 2005-03-27

Family

ID=22780858

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001119156/13A RU2249041C2 (en) 1998-12-10 1999-12-08 Method for preparing and isolating protein eliciting activity of factor viii, strain of cells hkb expressing protein eliciting activity of factor viii (variants)

Country Status (26)

Country Link
US (10) US6358703B1 (en)
EP (1) EP1137797B1 (en)
JP (1) JP4240818B2 (en)
KR (1) KR100616028B1 (en)
AT (1) ATE412765T1 (en)
AU (1) AU761801B2 (en)
BG (1) BG65431B1 (en)
BR (1) BRPI9916069B8 (en)
CA (1) CA2354845C (en)
CZ (1) CZ302330B6 (en)
DE (1) DE69939839D1 (en)
DK (1) DK1137797T3 (en)
ES (1) ES2315026T3 (en)
HU (1) HU228489B1 (en)
IL (2) IL143353A0 (en)
NO (1) NO329544B1 (en)
NZ (1) NZ512234A (en)
PL (1) PL200676B1 (en)
PT (1) PT1137797E (en)
RO (1) RO121604B1 (en)
RU (1) RU2249041C2 (en)
SI (1) SI20644B (en)
SK (1) SK286945B6 (en)
TR (1) TR200101592T2 (en)
UA (1) UA77383C2 (en)
WO (1) WO2000034505A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
US6180108B1 (en) * 1998-12-10 2001-01-30 Bayer Corporation Vectors having terminal repeat sequence of Epstein-Barr virus
AU5471501A (en) * 2000-03-22 2001-10-03 Octagene Gmbh Production of recombinant blood clotting factors in human cell lines
AU2002310438B2 (en) * 2001-06-14 2008-05-01 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
ES2911435T3 (en) 2003-02-26 2022-05-19 Nektar Therapeutics Factor VIII polymer-moiety conjugates
US7485291B2 (en) * 2003-06-03 2009-02-03 Cell Genesys, Inc. Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof
JP4644663B2 (en) * 2003-06-03 2011-03-02 セル ジェネシス インコーポレイテッド Construction and method for enhanced expression of recombinant polypeptides from a single vector using peptide cleavage sites
WO2006050050A2 (en) * 2004-10-29 2006-05-11 Centocor, Inc. Chemically defined media compositions
KR101654011B1 (en) 2004-11-12 2016-09-05 바이엘 헬스케어 엘엘씨 Site-directed modification of fviii
EP1969007B1 (en) 2005-12-20 2013-08-28 Bristol-Myers Squibb Company Compositions and methods for producing a composition
AR058568A1 (en) 2005-12-20 2008-02-13 Bristol Myers Squibb Co METHODS TO PRODUCE A COMPOSITION WITH CTLA4-IG MOLECULES FROM A CROP MEANS
EP2574676B1 (en) 2007-12-27 2017-08-30 Baxalta GmbH Cell culture processes
KR101005967B1 (en) * 2008-04-12 2011-01-05 (주)셀트리온 Human host cell for producing recombinant proteins with high quality and quantity
CA2728708A1 (en) * 2008-06-25 2009-12-30 Bayer Healthcare Llc Factor viii muteins with reduced immunogenicity
AU2009284113B2 (en) 2008-08-21 2015-05-14 Octapharma Ag Recombinantly produced human factor VIII and IX
WO2010026186A1 (en) * 2008-09-03 2010-03-11 Octapharma Ag New protecting compositions for recombinantly produced factor viii
WO2010091122A1 (en) 2009-02-03 2010-08-12 Amunix, Inc. Extended recombinant polypeptides and compositions comprising same
EP2411024A4 (en) * 2009-03-24 2013-02-27 Bayer Healthcare Llc Factor viii variants and methods of use
US20120263701A1 (en) 2009-08-24 2012-10-18 Volker Schellenberger Coagulation factor vii compositions and methods of making and using same
US20110150843A1 (en) * 2009-10-30 2011-06-23 National Institute Of Immunology Method for the therapeutic correction of hemophilia a by transplanting bone marrow cells
US20130017997A1 (en) * 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
EP3626737B1 (en) * 2011-05-13 2023-11-29 Octapharma AG A method of increasing the productivity of eucaryotic cells in the production of recombinant fviii
CN104271150A (en) 2012-01-12 2015-01-07 比奥根艾迪克Ma公司 Chimeric factor viii polypeptides and uses thereof
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
LT2814840T (en) * 2012-02-15 2020-02-25 Bioverativ Therapeutics Inc. Factor viii compositions and methods of making and using same
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
DK4176894T3 (en) 2014-01-10 2024-05-27 Bioverativ Therapeutics Inc CHIMERIC FACTOR VIII PROTEINS AND USES THEREOF
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
EA201892347A1 (en) 2016-04-15 2019-04-30 Баксалта Инкорпорейтед METHOD AND DEVICE FOR PROVIDING PHARMACOKINETIC SCHEME OF DOSING OF DRUGS
US11628205B2 (en) 2016-07-22 2023-04-18 Nektar Therapeutics Conjugates of a factor VIII moiety having an oxime-containing linkage
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
WO2019055717A1 (en) * 2017-09-13 2019-03-21 Evolve Biosystems, Inc. Oligosaccharide compositions and their use during transitional phases of the mammalian gut microbiome
KR20190086269A (en) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 Long-acting recombinant glycoproteins and menufacturing method thereof
AU2019270184A1 (en) 2018-05-18 2020-11-26 Bioverativ Therapeutics Inc. Methods of treating hemophilia A
JP2022512787A (en) * 2018-10-23 2022-02-07 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア Compositions and Methods for Modulating Factor VIII Function

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6045849B2 (en) 1980-08-25 1985-10-12 林原 健 Method for producing human erythropoietin
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
KR890002004B1 (en) * 1984-01-11 1989-06-07 가부시끼 가이샤 도오시바 Distinction apparatus of papers
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
AU5772886A (en) 1985-04-12 1986-11-05 Genetics Institute Inc. Novel procoagulant proteins
US5198349A (en) 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
DE3769872D1 (en) * 1986-07-11 1991-06-13 Miles Inc PRODUCTION OF RECOMBINANT PROTEIN.
DK175363B1 (en) 1986-09-12 2004-09-13 Genentech Inc Process for Continuous Production of a Desired Heterologous Protein in a Eukaryotic Host Cell, Vector Adding That Ability, and Cells Transformed with the Vector
IL86693A (en) * 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
SE465222C5 (en) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab A recombinant human factor VIII derivative and process for its preparation
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
ATE272122T1 (en) * 1993-06-10 2004-08-15 Bayer Ag VECTORS AND CELL LINES OF MAMMALS WITH INCREASED PRODUCTIVITY
US5952198A (en) * 1995-05-04 1999-09-14 Bayer Corporation Production of recombinant Factor VIII in the presence of liposome-like substances of mixed composition
DE19517194A1 (en) * 1995-05-11 1996-11-14 Giesecke & Devrient Gmbh Device and method for checking sheet material, e.g. Banknotes or securities
MX9504215A (en) 1995-10-05 1997-04-30 Inst Politecnico Nacional Improved process to purify oligopeptides with molecular weights from 1,000 to 10,000 daltons, from leukocyte extracts and their pharmaceutical presentation.
US5922959A (en) * 1996-10-15 1999-07-13 Currency Systems International Methods of measuring currency limpness
US5923413A (en) * 1996-11-15 1999-07-13 Interbold Universal bank note denominator and validator
US5804420A (en) * 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
AU735763B2 (en) * 1997-12-05 2001-07-12 Immune Response Corporation, The Novel vectors and genes exhibiting increased expression
US6040584A (en) * 1998-05-22 2000-03-21 Mti Corporation Method and for system for detecting damaged bills
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
US6136599A (en) * 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
US6180108B1 (en) 1998-12-10 2001-01-30 Bayer Corporation Vectors having terminal repeat sequence of Epstein-Barr virus
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII

Similar Documents

Publication Publication Date Title
RU2001119156A (en) The expression system for factor VIII
JP2766781B2 (en) Microorganisms capable of producing bovine growth hormone
EP0246279B1 (en) Method for isolation of recombinant polypeptides in biologically active forms
Ohno Evolution by gene duplication
US5693499A (en) Process for preparing human coagulation factor VIII protein complex
US6229003B1 (en) Production of bovine growth hormone by microorganisms
CN102358902B (en) Silkworm fibroin heavy-chain gene mutation sequence and mutation method and application
RU2009139802A (en) ENZYME FOR SYNTHESIS OF METHYLMONONYL-CO-ENZYME A AND ETHYLMALONYL-CO-ENZYME A, AND ITS APPLICATION
WO2000056900A3 (en) Promoter sequences derived from fusarium venenatum and uses thereof
SI20644B (en) Expression system for factor viii
HUP0101136A2 (en) Protein expression in baculovirus vector expression systems
RU2005117217A (en) A NEW ALDOLASE AND METHOD FOR PRODUCING OPTICALLY ACTIVE IHOG AND MONATINE
RU2005136013A (en) PHOSPHODYESTERASE 8A
AU2432095A (en) Production of biologically active recombinant neurotrophic protein
KR920004571A (en) Gene encoding heparin binding neurotrophic factor (HBNF), expression vectors and host cells comprising the same, and methods for producing and using HBNF
JP2003506077A (en) Recombinant stable cell clone, its production and use
JP2003506015A5 (en)
Morley Modulation of the action of regulatory peptides by structural modification
AU1941597A (en) Protein having cellulase activities and process for producing the same
CA2298412A1 (en) Identification of human cell lines for the production of human proteins by endogenous gene activation
KR890701606A (en) Production of animal lysozyme via secretion from Peachia pastoris and composition for same
EP0247145B1 (en) Multiply-amplifiable vectors for high level expression of exogenous dna
Engelmann Induction of the insect vitellogenin in vivo and in vitro
KR840004276A (en) Vector system containing auxiliary DNA for transforming eukaryotic cells
RU96122169A (en) NON-SPLICING OPTIONS GP350 / 220